Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.

BACKGROUND beta-Adrenergic agonists exert physiologic effects that are the opposite of those of beta-blockers. beta-Blockers are known to reduce morbidity and mortality in patients with cardiac disease. beta(2)-Agonist use in patients with obstructive airway disease has been associated with an increased risk for myocardial infarction, congestive heart failure, cardiac arrest, and acute cardiac death. OBJECTIVES To assess the cardiovascular safety of beta(2)-agonist use in patients with obstructive airway disease, defined as asthma or COPD. METHODS A meta-analysis of randomized placebo-controlled trials of beta(2)-agonist treatment in patients with obstructive airway disease was performed, to evaluate the short-term effect on heart rate and potassium concentrations, and the long-term effect on adverse cardiovascular events. Longer duration trials were included in the analysis if they reported at least one adverse event. Adverse events included sinus and ventricular tachycardia, syncope, atrial fibrillation, congestive heart failure, myocardial infarction, cardiac arrest, or sudden death. RESULTS Thirteen single-dose trials and 20 longer duration trials were included in the study. A single dose of beta(2)-agonist increased the heart rate by 9.12 beats/min (95% confidence interval [CI], 5.32 to 12.92) and reduced the potassium concentration by 0.36 mmol/L (95% CI, 0.18 to 0.54), compared to placebo. For trials lasting from 3 days to 1 year, beta(2)-agonist treatment significantly increased the risk for a cardiovascular event (relative risk [RR], 2.54; 95% CI, 1.59 to 4.05) compared to placebo. The RR for sinus tachycardia alone was 3.06 (95% CI, 1.70 to 5.50), and for all other events it was 1.66 (95% CI, 0.76 to 3.6). CONCLUSION beta(2)-Agonist use in patients with obstructive airway disease increases the risk for adverse cardiovascular events. The initiation of treatment increases heart rate and reduces potassium concentrations compared to placebo. It could be through these mechanisms, and other effects of beta-adrenergic stimulation, that beta(2)-agonists may precipitate ischemia, congestive heart failure, arrhythmias, and sudden death.

[1]  S. Salpeter.  Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease , 2004 .

[2]  M. Michel,et al.  Effect of prednisolone and ketotifen onβ2-adrenoceptors in asthmatic patients receivingβ2-bronchodilators , 2004, European Journal of Clinical Pharmacology.

[3]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[4]  E. Salpeter,et al.  Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. , 2003, Respiratory medicine.

[5]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[6]  K. Chatterjee,et al.  Role of nonglycosidic inotropic agents: indications, ethics, and limitations. , 2003, The Medical clinics of North America.

[7]  C. Solares,et al.  Tachycardia-induced cardiomyopathy. , 2003, The American journal of medicine.

[8]  T. Raghunathan,et al.  Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest , 2002 .

[9]  M. Sears.  Adverse effects of -agonists , 2002 .

[10]  C. Bulpitt,et al.  Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. , 2002, Archives of internal medicine.

[11]  E. Salpeter,et al.  Cardioselective -Blockers in Patients with Reactive Airway Disease , 2002, Annals of Internal Medicine.

[12]  O. Obeidat,et al.  Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study. , 2002, Journal of cardiac failure.

[13]  C. Rodrigo,et al.  Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. , 2002, Chest.

[14]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[15]  Paolo Palatini,et al.  Heart rate during myocardial infarction: relationship with one-year global mortality in men and women. , 2002, The Canadian journal of cardiology.

[16]  R. Goldstein,et al.  The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.

[17]  M. Decramer,et al.  Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial , 2002, European Respiratory Journal.

[18]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[19]  L. Goldman,et al.  beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. , 2002, JAMA.

[20]  J. Curtis,et al.  Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. , 2002, Chest.

[21]  David Skoner,et al.  Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. , 2001, The Journal of allergy and clinical immunology.

[22]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[23]  S. Giampaoli,et al.  Heart rate as a predictor of mortality: the MATISS project. , 2001, American journal of public health.

[24]  Lipworth Bj.  Revisiting interactions between hypoxaemia and beta2 agonists in asthma. , 2001 .

[25]  P. Sterk,et al.  Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients , 2001, Thorax.

[26]  C Guérot,et al.  Resting heart rate as a predictive risk factor for sudden death in middle-aged men. , 2001, Cardiovascular research.

[27]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[28]  A. Cartier,et al.  Effectiveness and safety of salmeterol in nonspecialist practice settings. , 2001, Chest.

[29]  W. Lumry,et al.  A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  M. Berger,et al.  Effects of on‐demand β2‐agonist inhalation in moderate‐to‐severe asthma. A randomized controlled trial , 2000, Journal of internal medicine.

[31]  B. Psaty,et al.  The Risk of Myocardial Infarction Associated with Inhaled β -Adrenoceptor Agonists , 2000 .

[32]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[33]  R. Dahl,et al.  Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. , 1999, Respiratory medicine.

[34]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[35]  E Casiglia,et al.  High heart rate: a risk factor for cardiovascular death in elderly men. , 1999, Archives of internal medicine.

[36]  B. Prillaman,et al.  Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[37]  L Guize,et al.  Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. , 1999, Hypertension.

[38]  Malcolm W Johnson.  The β -Adrenoceptor , 1998 .

[39]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[40]  M. Cazzola,et al.  Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. , 1998, Chest.

[41]  W. Bria,et al.  Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients. , 1998, Chest.

[42]  N. Dunn,et al.  Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2 agonists , 1998, Thorax.

[43]  S. Julius,et al.  Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. , 1998, European heart journal.

[44]  J. Crane,et al.  The extrapulmonary effects of increasing doses of formoterol in patients with asthma , 1998, European Journal of Clinical Pharmacology.

[45]  G. Emilien,et al.  Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists , 1998, European Journal of Clinical Pharmacology.

[46]  T. Kuusela,et al.  The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. , 1997, British journal of clinical pharmacology.

[47]  P. Barnes,et al.  Effect of short- and long-acting β2-adrenoceptor agonists on pulmonary β2-adrenoceptor expression in human lung , 1996 .

[48]  B. Hemmelgarn,et al.  Bronchodilators and acute cardiac death. , 1996, American journal of respiratory and critical care medicine.

[49]  P. Paré,et al.  Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. , 1996, Chest.

[50]  M. Sears,et al.  The beta-agonist controversy. , 1996, The Medical clinics of North America.

[51]  D. Cockcroft,et al.  Rapid onset of tolerance to the bronchoprotective effect of salmeterol. , 1995, Chest.

[52]  D. Yates,et al.  Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. , 1995, American journal of respiratory and critical care medicine.

[53]  G. Boyd.  Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. , 1995, The European respiratory journal.

[54]  J. Kemp,et al.  Safety of salmeterol in the maintenance treatment of asthma. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[55]  B. Gersh,et al.  Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study. , 1995, American journal of epidemiology.

[56]  I. Ziment.  The β-Agonist Controversy: Impact in COPD , 1995 .

[57]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[58]  I. Pavord,et al.  Systemic effects of salbutamol and salmeterol in patients with asthma. , 1994, Thorax.

[59]  I. D. Johnston,et al.  Effect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: a controlled study. , 1994, Respiration; international review of thoracic diseases.

[60]  I. Pavord,et al.  Asthma control during and after cessation of regular beta 2-agonist treatment. , 1993, The American review of respiratory disease.

[61]  G. Steinbeck,et al.  A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. , 1992, The New England journal of medicine.

[62]  N. Pearce,et al.  Cardiovascular effects of fenoterol under conditions of hypoxaemia. , 1992, Thorax.

[63]  M. Kendall,et al.  Metabolic effects of β2‐agonists , 1992 .

[64]  E. Robin,et al.  Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. , 1992, Chest.

[65]  R. Raper,et al.  Profound, reversible, myocardial depression in acute asthma treated with high‐dose catecholamines , 1992, Critical care medicine.

[66]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[67]  B. Lipworth.  Risks Versus Benefits of Inhaled β2-Agonists in the Management of Asthma , 1992 .

[68]  R. Dahl,et al.  Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. , 1991, The European respiratory journal.

[69]  S. Braun,et al.  Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. , 1991, The American journal of medicine.

[70]  D. Weich,et al.  Beta-adrenergic receptor tachyphylaxis in acute severe asthma. A preliminary communication. , 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[71]  R. N. Brogden,et al.  Atenolol , 1991, Drugs.

[72]  J. Feldman,et al.  Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. , 1991, American heart journal.

[73]  N. Douglas,et al.  Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. , 1990, BMJ.

[74]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[75]  I. Pavord,et al.  Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma , 1990, The Lancet.

[76]  R. Siebers,et al.  The pulmonary and extrapulmonary effects of inhaled β‐agonists in patients with asthma , 1990 .

[77]  B. Lipworth,et al.  Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[78]  J. Britton,et al.  High-dose inhaled albuterol in severe chronic airflow limitation. , 1988, The American review of respiratory disease.

[79]  J. Mattera,et al.  Oral terbutaline augments cardiac performance in chronic obstructive pulmonary disease. , 1988, The American journal of the medical sciences.

[80]  D. Lane,et al.  CARDIAC ARRHYTHMIAS CAUSED BY NEBULISED BETA-AGONIST THERAPY , 1987, The Lancet.

[81]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[82]  J. Paterson,et al.  Adverse Reactions to β2-Agonist Bronchodilators , 1986 .

[83]  A. Buist,et al.  Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline. , 1986, Chest.

[84]  H. Sluiter,et al.  Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. , 1985, The Journal of allergy and clinical immunology.

[85]  L A Borgen,et al.  A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma. , 1985, The Journal of allergy and clinical immunology.

[86]  J. Nordrehaug,et al.  Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. , 1985, Circulation.

[87]  A. Bundgaard,et al.  Cardiovascular effects of intramuscular or inhaled terbutaline in asthmatics. , 2009, Acta pharmacologica et toxicologica.

[88]  P. Corris,et al.  Nebulised salbutamol and angina. , 1982, British medical journal.

[89]  M. Tandon.  Cardiopulmonary effects of fenoterol and salbutamol aerosols. , 1980, Chest.

[90]  G. Kurland,et al.  Fatal myocardial toxicity during continuous infusion intravenous isoproterenol therapy of asthma. , 1979, The Journal of allergy and clinical immunology.

[91]  E. Wilkins,et al.  Fenoterol in asthma. , 1979, British journal of diseases of the chest.

[92]  N. Berend,et al.  Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. , 1978, British journal of clinical pharmacology.

[93]  S. Spector,et al.  Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols. , 1977, The Journal of allergy and clinical immunology.

[94]  Rowlands Df.  Letter: Poliomyelitis today. , 1976 .

[95]  N. Soler,et al.  Letter: Deaths in asthma. , 1975, British medical journal.

[96]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[97]  M. Lockett.  DANGEROUS EFFECTS OF ISOPRENALINE IN MYOCARDIAL FAILURE. , 1965, Lancet.

[98]  K. Lindahl-Kiessling,et al.  USE AND ABUSE OF ELECTROENCEPHALOGRAPHY. , 1964, Lancet.

[99]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[100]  W E POEL,et al.  Effect of carcinogenic dosage and duration of exposure on skin-tumor induction in mice. , 1959, Journal of the National Cancer Institute.